Financials disclosed in this offering
FY2023–FY2024 · hover for sourceThe fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Amendments to this offering
2 amendments- Jul 8, 2025
- Deadline Jul 18, 2025 → Aug 8, 2025
“20/20 Biolabs is extending their offering to August 8th, 2025.”
Form C/A on EDGAR ↗ - Jul 8, 2025No change to filed terms
“A reverse merger agreement mentioned in the SEC filing is no longer occurring and was removed from the offering materials.”
Form C/A on EDGAR ↗
Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.
Deal terms
No priced terms — this is a revenue-share or unpriced offering.
Offering details
Links & provenance
0001139685-25-000005
Last synced Aug 17, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.